NCT07885228
Jaktinib for Steroid-Refractory Acute Graft-Versus-Host Disease
StatusNot Yet Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Overall response rate (ORR)
Timeframe: Day 28
Secondary (10)
Durable overall response (DOR) at Day 56
Best Overall Response (BOR)
Overall response rate (ORR)
Overall Survival (OS)
Failure-Free Survival (FFS)
Show 5 moreShow less
Relapse-Free Survival (RFS)
Disease Relapse Rate
Event-Free Survival (EFS)
Incidence of Chronic Graft-Versus-Host Disease (cGVHD)
Safety and Tolerability (TEAEs)
Arms and interventions
Jaktinib ArmExperimental
Eligible participants with Grade II-IV steroid-refractory acute graft-versus-host disease (SR-aGVHD) will be assigned to this single group. All patients in this arm will receive Jaktinib treatment to evaluate its safety and clinical efficacy.
Drugs: Jaktinib
Sites
24 sites in 1 country